Company Directory - Eli Lilly And Co.
Company Details - Eli Lilly And Co.
Eli Lilly And Co.
WebsiteIndianapolis, United States
ISIN: US5324571083
An American pharmaceutical company that develops a wide range of medicines focusing on various therapeutic areas.
CCI Score
CCI Score: Eli Lilly And Co.
-35.34
0.02%
Latest Event
Eli Lilly Corporate Political Influence
Eli Lilly & Co exhibited significant political contributions of $1,863,367 and a lobbying expenditure of $6,720,000 in the 2024 cycle. The profile also highlights a revolving door phenomenon with a large proportion of lobbyists having held previous government positions, raising concerns over undue influence and regulatory capture.
Take Action
So what can you do? It's time to make tough choices. Where will you cast your vote?
- Shop Alternatives
SEE ALL - Use Your Voice
OTHER TOOLS - Investigate
- Share the Score
SUPPORT CCI
TOADIE
Eli Lilly And Co. is currently rated as a Toadie.
Latest Events
- FEB062025
Eli Lilly & Co exhibited significant political contributions of $1,863,367 and a lobbying expenditure of $6,720,000 in the 2024 cycle. The profile also highlights a revolving door phenomenon with a large proportion of lobbyists having held previous government positions, raising concerns over undue influence and regulatory capture.
-50
Political Contributions and Lobbying Efforts
March 31
Eli Lilly’s significant spending on lobbying and political contributions indicates an extensive investment in influencing policy. Such financial engagement from a major pharmaceutical company raises concerns about potential conflicts of interest and the promotion of policies that may serve elite interests at the expense of democratic accountability.
-30
Executive Political Engagement
March 31
The profile reveals a pronounced revolving door dynamic, with a majority of Eli Lilly's lobbyists having previously served in government positions. This close interconnection between corporate lobbying and government raises the risk of regulatory capture and portrays a problematic entanglement between public officials and corporate interests.
- DEC162024
Shareholders of Eli Lilly have urged the board to implement comprehensive human rights due diligence and produce a full Human Rights Impact Assessment (HRIA) covering operations, supplier practices, and product impacts. The resolution highlights deficiencies in Lilly’s current Code of Business Conduct, particularly its lack of clear mechanisms for monitoring worker rights and supply chain practices, raising concerns about potential forced labor and the company’s shifting focus from essential medicines like insulin.
-40
Public and Political Behavior
April 9
The shareholder resolution underscores a failure in proactive public accountability. Lilly’s lack of transparent action regarding human rights issues indicates an absence of robust public and political engagement from the company, thereby undermining trust and accountability in its governance.
-80
Labor Relations and Human Rights Practices
April 9
The resolution exposes a significant gap in Lilly's labor relations and human rights practices. The absence of a full human rights due diligence process and clear supplier monitoring mechanisms leaves worker rights inadequately protected and may enable human rights abuses, including the risk of forced labor in its supply chain.
- MAY032024
Public Citizen and shareholder advocates have criticized Eli Lilly for not disclosing detailed state and federal lobbying expenditures ahead of a shareholder vote, revealing significant omissions and a disconnect between its public claims of supporting lower drug prices and its actual lobbying practices.
-70
Political Contributions and Lobbying Efforts
April 9
Eli Lilly has been called out for failing to provide complete and transparent reporting on its lobbying expenditures. Public Citizen's analysis revealed that in a significant number of cases, the company omitted details regarding state-level lobbying spending and specific issues lobbied on. This lack of transparency undermines the trust of shareholders and suggests an alignment with opaque political influence tactics that can support authoritarian interests.
Eli Lilly Criticized For Not Disclosing Lobbying Expenses Ahead Of Shareholder Vote
- MAY032024
An analysis by Public Citizen revealed that Eli Lilly’s voluntary state lobbying disclosures fall significantly short of full transparency. The report found that in 52% of the state documents the company failed to disclose spending on lobbyists and in 73% failed to specify the issues lobbied on, with only 23% of cases providing complete information. This lack of full disclosure raises concerns about concealed political influence and corporate accountability.
-60
Political Contributions and Lobbying Efforts
April 9
The report exposes that Eli Lilly’s self-described extensive lobbying disclosures are in fact incomplete, with significant omissions regarding lobbying spending and the issues addressed in state-level activities. This failure to fully reveal its lobbying practices undermines transparency and accountability, potentially allowing undisclosed political influence to persist. From an anti-authoritarian perspective, hidden lobbying expenditures can contribute to unchecked political influence and risk corporate complicity in decisions that favor authoritarian agendas.
Despite Company Claims, Eli Lilly Fails to Disclose Its State Lobbying Spending for Half the Country
- APR022024
A federal judge granted conditional collective certification in an age discrimination lawsuit brought by Lilly sales representative Monica Richards. The suit alleges that Eli Lilly systematically denied promotions to employees over 40 in favor of hiring and promoting younger, millennial workers.
-70
Labor Relations and Human Rights Practices
March 31
The article outlines serious allegations that Eli Lilly has engaged in discriminatory practices by systematically denying older, qualified employees promotions in favor of younger candidates. This indicates poor labor relations and a disregard for human rights, underscoring a significant negative impact on fair employment practices.
Federal judge grants collective status in suit brought by Lilly worker who claimed age bias
- JAN012024
Eli Lilly has publicly detailed its political participation, including corporate contributions, extensive lobbying expenditures, and executive oversight through its Senior Vice President of Global Government Affairs and board mechanisms. The disclosure covers corporate and LillyPAC contributions made in 2024, along with detailed federal and state lobbying activities.
-60
Political Contributions and Lobbying Efforts
March 31
Eli Lilly discloses significant political contributions and lobbying expenditures, including $233,500 in corporate contributions, $1,228,700 via LillyPAC, and $7.89 million in federal lobbying. From an anti-fascist perspective, such extensive use of corporate funds to influence political processes reinforces corporate power over democratic policies and may undermine equitable public accountability.
Political and Party Participation | Policies & Reports | Eli Lilly and Company
-50
Executive Political Engagement
March 31
The active involvement of senior executives, notably the Senior Vice President of Global Government Affairs and board-level oversight, underscores how Eli Lilly leverages executive political engagement to shape policy outcomes. This concentrated corporate influence over political processes is viewed negatively from an anti-fascist perspective.
Political and Party Participation | Policies & Reports | Eli Lilly and Company
- JAN012024
The OpenSecrets profile reveals that Eli Lilly & Co. contributed approximately $1.86M and spent around $6.72M on lobbying during the 2024 election cycle. Additionally, the revolving door phenomenon, with many lobbyists having previously held government positions, underscores concerns over the firm's influence on policy-making.
-60
Political Contributions and Lobbying Efforts
April 9
Eli Lilly's substantial political contributions and lobbying expenditures, combined with a notable revolving door among its lobbyists, suggest an effort to shape policy that may undermine democratic accountability. Such corporate political influence is concerning from an anti-authoritarian perspective as it can facilitate policies that favor concentrated power and reduce transparency in governance.
- JAN012024
Eli Lilly disclosed details of its political participation in 2024, outlining its corporate contributions, lobbying expenditures, and executive oversight. The report reveals that the company made corporate contributions to state candidates, utilized its employee-funded LillyPAC for political donations, and spent nearly $7.89 million on federal lobbying. While the disclosures demonstrate transparency and structured board oversight, the sizeable financial outlays to influence policy raise concerns about corporate influence on democratic processes.
-40
Political Contributions and Lobbying Efforts
March 31
Eli Lilly’s sizable political contributions and lobbying expenditures—highlighted by over $7.8 million spent on federal lobbying and significant LillyPAC contributions—suggest that the company is leveraging its resources to shape policy. This heavy-handed political influence, even when transparently disclosed, can undermine democratic accountability and ensures corporate interests receive priority, a concerning trend from an anti-fascist perspective.
Political and Party Participation | Policies & Reports | Eli Lilly and Company
+10
Executive Political Engagement
March 31
The company demonstrates responsible executive oversight of its political engagements; its board and senior leadership actively review and approve political contributions and lobbying activities. This structured governance helps mitigate the risks of unchecked corporate influence.
Political and Party Participation | Policies & Reports | Eli Lilly and Company
- NOV012023
Data from OpenSecrets reveals that the Eli Lilly & Co PAC received 2,932 large contributions (over $200) from individual donors during the 2023-2024 election cycle. This disclosure highlights the company's involvement in political financing through its PAC.
-10
Political Contributions and Lobbying Efforts
April 9
The detailed report of 2,932 large contributions to the Eli Lilly & Co PAC underscores the company's engagement in political fundraising. From an anti-fascist perspective, reliance on significant political contributions can help sustain established power structures that may favor authoritarian interests. While the data reflects transparency from an external source (OpenSecrets) rather than a direct corporate initiative, the event signals potential alignment with mechanisms that could undermine democratic accountability.
- OCT112023
Eli Lilly and Co., along with its subsidiary Lilly USA, agreed to pay $2.4 million and implement corrective measures including EEO training and revised hiring practices to address a nationwide age discrimination lawsuit brought by the EEOC, which accused the company of discriminating against older applicants under its Early Career hiring initiative.
+80
Labor Relations and Human Rights Practices
April 9
By settling the age discrimination lawsuit and implementing measures to ensure fair hiring practices, Eli Lilly demonstrates a commitment to rectifying labor practices that excluded older workers. These steps align with pro-worker, anti-discrimination policies that support fair treatment and inclusivity in the workplace.
Lilly to Pay $2.4 Million to Settle Nationwide EEOC Age Discrimination Lawsuit
- OCT062023
The U.S. Justice Department has launched a criminal probe into alleged manufacturing irregularities and records tampering at an Eli Lilly facility in Branchburg, New Jersey, raising serious concerns about the company's internal ethical practices.
-40
Business Practices and Ethical Responsibility
March 31
The criminal investigation into alleged manufacturing irregularities and records tampering indicates potential unethical business practices and internal lapses at Eli Lilly. Such behavior undermines regulatory compliance and ethical standards, reflecting negatively on the company’s business practices and overall accountability.
Exclusive: U.S. opens criminal probe into alleged lapses at Eli Lilly ...
- SEP292023
Eli Lilly agreed to pay $22.5 million to settle a lawsuit brought by a former human resources officer who alleged wrongful termination and retaliation after raising concerns about quality and manufacturing violations at the Branchburg, NJ plant.
-70
Labor Relations and Human Rights Practices
March 31
The settlement following a whistleblower lawsuit highlights serious deficiencies in Eli Lilly’s labor practices, including alleged retaliation and failure to address critical safety and quality issues. Such actions undermine worker rights and ethical practices, reflecting poorly on the company's commitment to internal accountability.
Eli Lilly settles Whistleblower lawsuit over alleged quality issues
- SEP282023
Eli Lilly and Co. settled a lawsuit with a former employee who claimed she was terminated after reporting poor manufacturing practices and data falsification. The settlement raises concerns regarding the company’s treatment of whistleblowers and labor rights, suggesting deficiencies in ethical business practices.
-70
Labor Relations and Human Rights Practices
April 9
The lawsuit settlement, resulting from allegations that a whistleblower was terminated after exposing poor manufacturing practices and data falsification, indicates a failure to uphold strong labor relations and human rights standards. This reflects negatively on the company's ethical responsibility towards its workers.
Eli Lilly settles whistleblower lawsuit over manufacturing problems
- AUG272023
Eli Lilly settled an age discrimination lawsuit for an undisclosed amount after allegations of excluding older candidates from hiring, following a previous $2.4M settlement with the EEOC. The settlements address claims that the company intentionally under-hired older applicants in favor of younger candidates.
-80
Labor Relations and Human Rights Practices
April 9
The settlement over age discrimination highlights systemic issues in Eli Lilly's hiring practices, reflecting a failure in upholding fair labor practices and protecting the rights of older workers. This practice undermines principles of human rights and ethical labor relations, making it a negative mark on the company's business practices and ethical responsibility profile.
Accused Of Excluding Older Applicants, Eli Lilly Settles Again - Forbes
- JUN012023
Eli Lilly CEO David Ricks made a $25,000 donation in June 2023 to the Committed to America super PAC supporting former Vice President Mike Pence, marking one of the first major political contributions from a prominent pharmaceutical leader ahead of the 2024 elections.
-60
Political Contributions and Lobbying Efforts
March 31
The donation by CEO David Ricks to a super PAC supporting Mike Pence—an influential political figure aligned with conservative and potentially authoritarian policies—demonstrates active corporate political involvement. This early major contribution signals preferential support for political movements that may undermine progressive and equitable governance.
Eli Lilly CEO donates big to Mike Pence presidential super PAC
-50
Executive Political Engagement
March 31
As the CEO directly engaging in a significant political donation, David Ricks exemplifies executive political engagement that channels corporate influence into partisan political processes. His personal action reinforces the company's indirect alignment with political ideologies that may foster authoritarian tendencies.
Eli Lilly CEO donates big to Mike Pence presidential super PAC
- JAN012023
Eli Lilly has resumed its political contributions to Indiana Republicans who voted against certifying the election, reversing its earlier decision made in the wake of the Capitol attack.
-70
Political Contributions and Lobbying Efforts
March 31
Eli Lilly's decision to resume political contributions to Republicans who opposed certifying the election indicates a reversion to supporting political actors who have been associated with anti-democratic behavior. This move suggests continued alignment with policies and practices that can undermine democratic accountability.
- JAN012023
The 2023 sustainability report on Eli Lilly’s website details the company’s robust initiatives to strengthen its supply chain governance, risk management, and supplier diversity. Notably, Lilly’s participation in the Pharmaceutical Supply Chain Initiative (PSCI), proactive third-party risk management, and leadership roles on industry boards underline its commitment to ethical practices and progressive political engagement.
+60
Executive Political Engagement
April 9
Lilly’s active involvement in industry governance—serving on boards such as Rx-360 and participating in working groups—demonstrates a commitment to progressive leadership and executive political engagement. Such actions help ensure that corporate policies lean towards transparency and diversity, resisting authoritarian influences.
Governance | 2023 Sustainability Report | Eli Lilly and Company
+75
Supply Chain Ethics
April 9
The report highlights Lilly’s comprehensive supply chain ethics framework, emphasizing strict adherence to UN Global Compact principles, detailed third-party risk management, and a strong commitment to supplier diversity. These measures contribute positively by protecting worker rights and supporting marginalized communities.
Governance | 2023 Sustainability Report | Eli Lilly and Company
Alternatives
Kenilworth, United States
2.89
Pasadena, United States
0.00
The Woodlands, United States
-29.63
North Chicago, United States
-31.53
Cambridge, United States
-33.87
Menlo Park, United States
-49.80
Bagsværd, Denmark
18.81
Thousand Oaks, USA
13.63
Basel, Switzerland
-19.75
Corporation
2.31
Corporate Financials
- Revenue
- 2025
- $26.00B
- Total Assets
- 2025
- $53.00B
- Operating Income
- 2025
- $8.00B
- Total Equity
- 2025
- $12.00B
Industries
- 325411
- Medicinal and Botanical Manufacturing
- 325412
- Pharmaceutical Preparation Manufacturing
- 541714
- Research and Development in Biotechnology (except Nanobiotechnology)
- 541715
- Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- 541711
- Research and Development in Biotechnology